Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography

Christopher S. Lee, Sungchul Lee, Kyungsik Lee, Hee J. Kwon, Jeong H. Yi, Arthur Cho

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: To evaluate regression rates of uveal melanoma after combined Ru-106 plaque radiotherapy and thermotherapy according to metabolic activity measured by positron emission tomography/computed tomography imaging. Methods: A retrospective medical chart review was conducted on 26 patients with uveal melanoma who underwent pretreatment whole-body positron emission tomography/computed tomography and received combined plaque radiotherapy and thermotherapy between 2006 and 2011. Tumors were classified as metabolically active and inactive based on the positron emission tomography/computed tomography imaging and compared with tumor height regression rates after treatment. Results: Before treatment, the median tumor thickness was 8.8 mm for metabolically active tumors (7 eyes) and 5.0 mm for metabolically inactive tumors (19 eyes). The median tumor thicknesses with respect to the original thickness at 3, 6, and 12 months after treatment were 88%, 78%, and 64% for metabolically active tumors and 95%, 89%, and 81% for metabolically inactive tumors, respectively. The monthly tumor regression rates during the first 3 months (4.2% vs. 1.7%, P = 0.022) and the overall monthly tumor regression rates (3.0% vs. 1.5%, P = 0.041) were significantly higher for metabolically active tumors versus inactive tumors. Two patients with positive metabolic activity developed metastatic diseases 2 years after treatment, whereas no patient with negative metabolic activity developed metastatic disease during the study period. Conclusion: Positive metabolic activity of uveal melanoma based on the positron emission tomography/computed tomography was significantly associated with rapid initial tumor regression after combined plaque radiotherapy and thermotherapy, suggesting a prognostic value for this diagnostic approach.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
JournalRetina
Volume34
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Induced Hyperthermia
Brachytherapy
Neoplasms
Radiotherapy
Positron Emission Tomography Computed Tomography
Uveal melanoma
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Lee, Christopher S. ; Lee, Sungchul ; Lee, Kyungsik ; Kwon, Hee J. ; Yi, Jeong H. ; Cho, Arthur. / Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. In: Retina. 2014 ; Vol. 34, No. 1. pp. 182-187.
@article{913c3ea10f6741b3bb8404a06ed60a10,
title = "Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography",
abstract = "Purpose: To evaluate regression rates of uveal melanoma after combined Ru-106 plaque radiotherapy and thermotherapy according to metabolic activity measured by positron emission tomography/computed tomography imaging. Methods: A retrospective medical chart review was conducted on 26 patients with uveal melanoma who underwent pretreatment whole-body positron emission tomography/computed tomography and received combined plaque radiotherapy and thermotherapy between 2006 and 2011. Tumors were classified as metabolically active and inactive based on the positron emission tomography/computed tomography imaging and compared with tumor height regression rates after treatment. Results: Before treatment, the median tumor thickness was 8.8 mm for metabolically active tumors (7 eyes) and 5.0 mm for metabolically inactive tumors (19 eyes). The median tumor thicknesses with respect to the original thickness at 3, 6, and 12 months after treatment were 88{\%}, 78{\%}, and 64{\%} for metabolically active tumors and 95{\%}, 89{\%}, and 81{\%} for metabolically inactive tumors, respectively. The monthly tumor regression rates during the first 3 months (4.2{\%} vs. 1.7{\%}, P = 0.022) and the overall monthly tumor regression rates (3.0{\%} vs. 1.5{\%}, P = 0.041) were significantly higher for metabolically active tumors versus inactive tumors. Two patients with positive metabolic activity developed metastatic diseases 2 years after treatment, whereas no patient with negative metabolic activity developed metastatic disease during the study period. Conclusion: Positive metabolic activity of uveal melanoma based on the positron emission tomography/computed tomography was significantly associated with rapid initial tumor regression after combined plaque radiotherapy and thermotherapy, suggesting a prognostic value for this diagnostic approach.",
author = "Lee, {Christopher S.} and Sungchul Lee and Kyungsik Lee and Kwon, {Hee J.} and Yi, {Jeong H.} and Arthur Cho",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/IAE.0b013e31829479fb",
language = "English",
volume = "34",
pages = "182--187",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography. / Lee, Christopher S.; Lee, Sungchul; Lee, Kyungsik; Kwon, Hee J.; Yi, Jeong H.; Cho, Arthur.

In: Retina, Vol. 34, No. 1, 01.01.2014, p. 182-187.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regression of uveal melanoma after RU-106 brachytherapy and thermotherapy based on metabolic activity measured by positron emission tomography/computed tomography

AU - Lee, Christopher S.

AU - Lee, Sungchul

AU - Lee, Kyungsik

AU - Kwon, Hee J.

AU - Yi, Jeong H.

AU - Cho, Arthur

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: To evaluate regression rates of uveal melanoma after combined Ru-106 plaque radiotherapy and thermotherapy according to metabolic activity measured by positron emission tomography/computed tomography imaging. Methods: A retrospective medical chart review was conducted on 26 patients with uveal melanoma who underwent pretreatment whole-body positron emission tomography/computed tomography and received combined plaque radiotherapy and thermotherapy between 2006 and 2011. Tumors were classified as metabolically active and inactive based on the positron emission tomography/computed tomography imaging and compared with tumor height regression rates after treatment. Results: Before treatment, the median tumor thickness was 8.8 mm for metabolically active tumors (7 eyes) and 5.0 mm for metabolically inactive tumors (19 eyes). The median tumor thicknesses with respect to the original thickness at 3, 6, and 12 months after treatment were 88%, 78%, and 64% for metabolically active tumors and 95%, 89%, and 81% for metabolically inactive tumors, respectively. The monthly tumor regression rates during the first 3 months (4.2% vs. 1.7%, P = 0.022) and the overall monthly tumor regression rates (3.0% vs. 1.5%, P = 0.041) were significantly higher for metabolically active tumors versus inactive tumors. Two patients with positive metabolic activity developed metastatic diseases 2 years after treatment, whereas no patient with negative metabolic activity developed metastatic disease during the study period. Conclusion: Positive metabolic activity of uveal melanoma based on the positron emission tomography/computed tomography was significantly associated with rapid initial tumor regression after combined plaque radiotherapy and thermotherapy, suggesting a prognostic value for this diagnostic approach.

AB - Purpose: To evaluate regression rates of uveal melanoma after combined Ru-106 plaque radiotherapy and thermotherapy according to metabolic activity measured by positron emission tomography/computed tomography imaging. Methods: A retrospective medical chart review was conducted on 26 patients with uveal melanoma who underwent pretreatment whole-body positron emission tomography/computed tomography and received combined plaque radiotherapy and thermotherapy between 2006 and 2011. Tumors were classified as metabolically active and inactive based on the positron emission tomography/computed tomography imaging and compared with tumor height regression rates after treatment. Results: Before treatment, the median tumor thickness was 8.8 mm for metabolically active tumors (7 eyes) and 5.0 mm for metabolically inactive tumors (19 eyes). The median tumor thicknesses with respect to the original thickness at 3, 6, and 12 months after treatment were 88%, 78%, and 64% for metabolically active tumors and 95%, 89%, and 81% for metabolically inactive tumors, respectively. The monthly tumor regression rates during the first 3 months (4.2% vs. 1.7%, P = 0.022) and the overall monthly tumor regression rates (3.0% vs. 1.5%, P = 0.041) were significantly higher for metabolically active tumors versus inactive tumors. Two patients with positive metabolic activity developed metastatic diseases 2 years after treatment, whereas no patient with negative metabolic activity developed metastatic disease during the study period. Conclusion: Positive metabolic activity of uveal melanoma based on the positron emission tomography/computed tomography was significantly associated with rapid initial tumor regression after combined plaque radiotherapy and thermotherapy, suggesting a prognostic value for this diagnostic approach.

UR - http://www.scopus.com/inward/record.url?scp=84891881959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891881959&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e31829479fb

DO - 10.1097/IAE.0b013e31829479fb

M3 - Article

VL - 34

SP - 182

EP - 187

JO - Retina

JF - Retina

SN - 0275-004X

IS - 1

ER -